NCT07394374 2026-02-06
A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities
Cullgen (Shanghai),Inc
Phase 1/2 Recruiting
Clinical Trials
5 trialsNCT02122913 2026-02-05
A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer
Bayer
Phase 1 Completed
NCT05192642 2023-11-14
A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice
Bayer
Completed
NCT04771390 2021-08-25
Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants
Bayer
Phase 1 Completed
NCT04275960 2020-12-29
Study in Healthy Adult Male Participants to Gather Information How the Human Body Absorbs, Distributes and Excretes the Study Drug Selitrectinib Including the Effect of the Interaction of Food With the Study Drug on the Human Body
Bayer
Phase 1 Completed